Enhanced Radix Polygalae Extract Formulations for Improved ADHD Treatment

This inventive concept presents novel formulations and methods for treating attention-deficit hyperactivity disorder (ADHD) using Radix Polygalae extract, addressing the limitations of the original patent by enhancing efficacy, bioavailability, and personalized treatment options.

The original patent disclosed a method for treating ADHD using Radix Polygalae extract, but it had limitations in terms of efficacy, absorption, and individualized treatment. The new inventive concept addresses these limitations by introducing synergistic agents, liposomal formulations, omega-3 fatty acid combinations, personalized genetic profiling, and sustained-release dosage forms to provide more effective and targeted treatment options.

The new inventive concept encompasses five distinct approaches: (1) a system combining Radix Polygalae extract with a synergistic agent to enhance efficacy, (2) a liposomal formulation to increase bioavailability, (3) a composition combining Radix Polygalae extract with omega-3 fatty acids to potentiate therapeutic effects, (4) a method for personalized treatment using genetic profiling to optimize dosage, and (5) a sustained-release dosage form to provide consistent and prolonged therapeutic effects. These approaches overcome the limitations of the original patent and offer improved treatment options for ADHD patients.

The new inventive concept introduces novel combinations, formulations, and methods that are not obvious from the original patent. The use of synergistic agents, liposomal formulations, omega-3 fatty acid combinations, genetic profiling, and sustained-release dosage forms provides a significant improvement over the original patent, making the new inventive concept novel and non-obvious.

Alternative embodiments of the inventive concept could include different synergistic agents, various liposomal formulations, and alternative combinations of omega-3 fatty acids. Additionally, the genetic profiling method could be adapted for use with other genetic markers or biomarkers. The sustained-release dosage form could be modified to provide different release profiles or combined with other therapeutic agents.

The enhanced Radix Polygalae extract formulations and methods have significant commercial potential in the pharmaceutical industry, particularly in the ADHD treatment market. The new inventive concept offers a competitive advantage in terms of efficacy, safety, and personalized treatment options, making it an attractive solution for patients, healthcare providers, and pharmaceutical companies.